There is convincing evidence that endogenous cannabinoids exist in both the brain and the immune system. Two G-protein cannabinoid receptors have been cloned. one is found throughout the brain in high concentrations, as well as in several peripheral tissues, whereas the other is localized exclusively in the periphery. The isolation and identification of endogenous cannabinoids, such as anandamide, led to intensified efforts to understand the functional significance of endogenous cannabinoids. Manipulation of these endogenous ligands should reveal their functional role, especially as mediated through cannabinoid receptors, and lead to a better understanding of the etiology of cannabis abuse, identification of therapeutic uses of cannabinoids, and establishment of either deleterious or protective effects on the immune system. Studies on the immune system are important since they may allow for articulation of a mechanism by which endogenous cannabinoids modulate immune function. Such modulation may be of consequence among immune compromised individuals, especially AIDS patients. The recent development of selective antagonists for cannabinoid receptor subtypes serve as exciting new probes for fulfilling these objectives. The purpose of this proposal is to continue this multidisciplinary program that will consist of five research projects and an administrative core, to define the functional role of endogenous cannabinoids. Each P.I. is an experienced researcher who will make a unique contribution. Professor Mechoulam proposes to isolate and identify other endogenous substances that modulate the activity of anandamide as well as conduct a synthetic program. Dr. Razdan will continue his synthetic program in which he will provide novel and innovate probes to the other members of the research team. His objectives include preparation of stable and highly potent analogs of the endogenous substances and analogs of SR141716A. Research teams led by Drs. Martin and Pertwee will conduct pharmacological evaluation of endogenous ligands and analogs of endogenous agonists and of the antagonist. These groups also will use both tolerance development and the antagonist to explore the plasticity of the receptor and gene expression. Dr. Martin will address the dependence liability of anandamide. Dr. Kaminski proposes to establish the effects of endogenous ligands on the immune system and to elucidate a natural role of cannabinoids in immune function. Dr. Kaminski has evidence that two endogenous ligands exert different effects on immune cells. The participants have already demonstrated that their collaborative efforts have been most productive and fruitful.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Program Projects (P01)
Project #
2P01DA009789-04
Application #
2673273
Study Section
Special Emphasis Panel (ZDA1-MXC-A (11))
Program Officer
Rapaka, Rao
Project Start
1995-09-15
Project End
2001-08-31
Budget Start
1998-09-30
Budget End
1999-08-31
Support Year
4
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Virginia Commonwealth University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
City
Richmond
State
VA
Country
United States
Zip Code
23298
Donvito, Giulia; Nass, Sara R; Wilkerson, Jenny L et al. (2018) The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain. Neuropsychopharmacology 43:52-79
Wilkerson, Jenny L; Curry, Zachary A; Kinlow, Pamela D et al. (2018) Evaluation of different drug classes on transient sciatic nerve injury-depressed marble burying in mice. Pain 159:1155-1165
Mitjavila, Jose; Yin, Danielle; Kulkarni, Pushkar M et al. (2018) Enantiomer-specific positive allosteric modulation of CB1 signaling in autaptic hippocampal neurons. Pharmacol Res 129:475-481
Wilkerson, Jenny L; Ghosh, Sudeshna; Mustafa, Mohammed et al. (2017) The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice. Neuropharmacology 114:156-167
Wilkerson, Jenny L; Niphakis, Micah J; Grim, Travis W et al. (2016) The Selective Monoacylglycerol Lipase Inhibitor MJN110 Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model. J Pharmacol Exp Ther 357:145-56
Buczynski, Matthew W; Herman, Melissa A; Hsu, Ku-Lung et al. (2016) Diacylglycerol lipase disinhibits VTA dopamine neurons during chronic nicotine exposure. Proc Natl Acad Sci U S A 113:1086-91
Staiano, Rosaria I; Loffredo, Stefania; Borriello, Francesco et al. (2016) Human lung-resident macrophages express CB1 and CB2 receptors whose activation inhibits the release of angiogenic and lymphangiogenic factors. J Leukoc Biol 99:531-40
Tessaris, Daniele; Matarazzo, Patrizia; Lala, Roberto et al. (2016) Odontoiatric perspectives and osteonecrosis of the jaw as a possible adverse effect of bisphosphonates therapy in fibrous dysplasia and McCune-Albright syndrome. J Pediatr Endocrinol Metab 29:333-6
Kocova, Mirjana; Zdraveska, Nikolina; Kacarska, Rozana et al. (2016) Diagnostic approach in children with unusual symptoms of acquired hypothyroidism. When to look for pituitary hyperplasia? J Pediatr Endocrinol Metab 29:297-303
Anavi-Goffer, Sharon; Ross, Ruth A (2016) A Functional Assay for GPR55: Envision Protocol. Methods Mol Biol 1412:77-83

Showing the most recent 10 out of 270 publications